Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Effectiveness of a killed whole-cell oral cholera vaccine in Bangladesh: further follow-up of a cluster-randomised trial

Mohammad Ali, Firdausi Qadri*, Deok Ryun Kim, Md Taufiqul Islam, Justin Im, Faisal Ahmmed, Ashraful Islam Khan, K Zaman, Florian Marks, Jerome H Kim, John D Clemens

Summary

Background KILLED whole-cell oral cholera vaccines (OCVs) are widely used for prevention of cholera in developing countries. However, few studies have evaluated the protection conferred by internationally recommended OCVs for durations beyond 2 years of follow-up.

Methods In this study, we followed up the participants of a cluster-randomised controlled trial for 2 years after the end of the original trial. Originally, we had randomised 90 geographical clusters in Dhaka slums in Bangladesh in equal numbers (1:1:1) to a two-dose regimen of OCV alone (targeted to people aged 1 year or older), a two-dose regimen of OCV plus a water–sanitation–hygiene (WASH) intervention, or no intervention. There was no masking of group assignment. The WASH intervention conferred little additional protection to OCV and was discontinued at 2 years of follow-up. Surveillance for severe cholera was continued for 4 years. Because of the short duration and effect of the WASH intervention, we combined the two OCV intervention groups. The primary outcomes were OCV overall protection (protection of all members of the intervention clusters) and total protection (protection of individuals who got vaccinated in the intervention clusters) against severe cholera, which we assessed by multivariable survival models appropriate for cluster-randomised trials. This trial is registered on ClinicalTrials.gov, NCT01339845.

Findings The study was done between April 17, 2011, and Nov 1, 2015. 268 896 participants were present at the time of the first dose, with 188 206 in the intervention group and 80 690 in the control group. OCV coverage of the two groups receiving OCV was 66% (123 659 of 187 214 participants). During 4 years of follow-up, 441 first episodes of severe cholera were detected (243 episodes in the vaccinated groups and as 198 episodes in the unvaccinated group). Overall OCV protection was 36% (95% CI 19 to 49%) and total OCV protection was 46% (95% CI 32 to 58). Cumulative total vaccine protection was notably lower for people vaccinated before the age of 5 years (24%; –30 to 56) than for people vaccinated at age 5 years or older (49%; 35 to 60), although the differences in protection for the two age groups were not significant (p=0·3308). Total vaccine protection dropped notably (p=0·0115) after 3 years in children vaccinated at 1–4 years of age.

Interpretation These findings provide further evidence of long-term effectiveness of killed whole-cell OCV, and therefore further support for the use of killed whole-cell OCVs to control endemic cholera, but indicate that protection is shorter-lived in children vaccinated before the age of 5 years than in people vaccinated at the age of 5 years or older.

Funding Bill & Melinda Gates Foundation.

Introduction It is clear that provision of clean water and adequate sanitation as well as the maintenance of good personal hygiene (WASH) stops the transmission of cholera. Affluent countries have implemented these adequate levels of WASH by major investments into municipal WASH infrastructure. Unfortunately, the financial costs of such improvements are currently beyond the reach of most low-income and middle-income countries (LMICs), and cholera continues to thrive in many of these settings, accounting for a major burden of morbidity and mortality globally. While awaiting such improvements in poorer countries, recent efforts to prevent cholera have focused largely on delivery of low cost, oral cholera vaccines (OCVs) based on killed whole cells (WCs), which have been shown to be safe and to confer substantial protection. Protection data for the vaccine Shanchol, which is used in the global OCV stockpile, have shown sustained protection for 4 years post-dosing in Haiti and 5 years post-dosing in Kolkata. Follow-up of a mass immunisation programme with a different killed WC-OCV found protection lasting for 5 years in Vietnam. However, similar but not identical inactivated OCVs tested in the first efficacy trial of inactivated OCVs, done in Bangladesh in 1985, revealed protection lasting only 2–3 years. In 2011, we initiated a large-scale, cluster-randomised trial in urban Bangladesh to assess whether Shanchol, a WHO-prequalified, killed WC-only OCV, could protect against severe cholera in densely populated slums with intense cholera transmission, and whether concomitant
**Research in context**

**Evidence before this study**

Killed whole-cell (WC) oral cholera vaccines (OCV) are internationally licensed and recommended, as well as stockpiled for use in cholera epidemics, in cholera-endemic populations, and in humanitarian emergencies. However, more evidence is needed on the long-term protection of these vaccines. We searched PubMed using the terms “oral cholera vaccine”, “Dukoral”, “Shanchol”, “whole cell inactivated cholera vaccine”, “clinical trial”, “vaccine efficacy”, and “vaccine effectiveness” to identify reports published in English between Jan 1, 1985, and April 1, 2020, investigating the protective effects of WC OCV. We identified studies done in India, Bangladesh, Haiti, and Vietnam, which reported protective effects of OCV for 4 years or longer after vaccination.

**Added value of this study**

To better understand the performance of killed WC OCV under programmatic conditions, we did a cluster-randomised effectiveness trial of killed WC OCV in urban slums of Dhaka, Bangladesh, where the burden of cholera disease is high. Our study found that vaccine (ie, Shanchol) protection against severe cholera was moderately high and sustained for at least 4 years in people vaccinated when aged 5 years or older, but was lower and only demonstrable for 3 years in children vaccinated at 1–4 years of age.

**Implications of all the available evidence**

Our findings support the programmatic usefulness of the Shanchol vaccine, but underscore the need to devise ways to improve protection of young children against cholera.

---

provision of an inexpensive WASH intervention enhanced this OCV protection. As reported elsewhere, at 2 years of follow-up, we observed substantial protection by the OCV, but little difference in protection with the addition of the WASH intervention. The WASH intervention was thereby discontinued at 2 years of follow-up, but surveillance was maintained for an additional 2 years. In this Article, we report on the findings for vaccine protection during this extended follow-up.

**Methods**

**Study design and participants**

This large-scale, cluster-randomised trial was done in urban slums in the Mirpur district of Dhaka City (which have a population of approximately 3 million people) in Bangladesh. Households with low socioeconomic status from the six wards of Mirpur (2, 4, 5, 6, 14, and 16) were selected for this study. The study protocol was approved by the Research Review Committee and the Ethical Review Committee of the International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b) and the Institutional Review Board of the International Vaccine Institute. Written informed consent was obtained from individuals older than 18 years and from the parents or guardians of individuals aged 1–17 years. Additional assent was obtained from individuals aged 12–17 years.

**Randomisation and masking**

The 90 geographical clusters in the area in Mirpur, of approximately equal size (average population was 2988; range 2288–4299), were randomised by a computer-generated sequence into three groups (1:1:1) of 30 clusters. Of the study’s three groups, one group received a two-dose regimen of the Shanchol vaccine alone (VAX group), one group a two-dose regimen of the Shanchol vaccine plus a behaviour change WASH intervention (VBCC group), and one group no intervention (control). The participants and investigators were aware of the group assignments. Each cluster was separated from the adjoining cluster by at least a 30 m buffer area, to minimise transmission of cholera and diffusion of the WASH intervention between clusters.

**Procedures**

Healthy, non-pregnant individuals aged 1 year or older from the VAX and VBCC clusters were invited to receive two doses of the bivalent WC inactivated OCV, Shanchol, at least 14 days apart. The vaccination campaign was done between Feb 17, 2011, and April 6, 2011. The behaviour change WASH intervention (BCC) intervention in the VBCC group was delivered by a non-governmental organisation and included installation of hand washing stations, distribution of soap and chlorine tablets, and community engagement and promotion. These interventions were continued up to August 2013. Details of the interventions can be found elsewhere.

**Outcomes**

The primary outcomes were OCV overall protection and total protection against severe cholera. Passive diarrhoeal disease surveillance was done by specially trained study staff at the two hospitals of the icddr,b and ten other hospitals located either inside or nearby the study area between April 17, 2011, and Nov 1, 2015. A diarrhoeal visit was defined as having three or more loose stools or one-to-two or an indeterminate number of loose stools in the past 24 h before presentation with evidence of dehydration according to WHO criteria. Diarrhoeal visits for which the date of onset was 7 days or less from the date of discharge for the previous visit were treated as the same episode. The onset of a diarrhoeal episode was the day on which the patient first reported loose or liquid stools before the first diarrhoeal visit of the episode. Patients from the study area were identified in the treatment centres by use of a household ID card, which they had been given for the project, and by searching the ID in an onsite computerised data system. Physicians did
the clinical examination and the project staff filled the data form and obtained faecal specimens after obtaining written informed consent. Faecal specimens were tested for *Vibrio cholerae* O1 and O139 serogroups and Inaba and Ogawa serotypes using conventional methods.\(^6\) Biotype was ascertained for all isolates.\(^6\) Severe cholera was defined as a diarrhoeal episode in which *V cholerae* O1 or O139 was isolated and severe dehydration, defined elsewhere,\(^7\) was detected in at least one constituent diarrhoeal visit of the episode.

**Statistical analysis**

For several reasons, we decided to merge the two vaccine groups of the trial for this analysis. First, our interest was in extended vaccine protection over the 4-year period of cholera surveillance after vaccination indicated in the study protocol, and the high migration rate of this population substantially reduced the baseline population still under follow-up during the 3rd and 4th years. Second, vaccine protection for the two vaccine groups was similar during the first 2 years of follow-up. Third, the BCC WASH intervention was stopped after 2 years and was not found to confer significant additional protection against severe cholera.\(^8\)

The start date for follow-up for analyses of vaccine protection was the date of the second dose for recipients of the second dose or the median date of the second dose in the cluster for non-recipients of the second dose in intervention clusters; for control clusters, the median date of the second dose in the nearest cluster of the intervention group was used. We evaluated overall vaccine effectiveness\(^9\) by comparing the occurrence of first episodes of severely dehydrating cholera during the 4-year post-vaccination period among all individuals present at zero time in the two intervention groups combined versus the control group. Zero time was defined as the date of dose one for vaccine recipients, and the median date of dose one in a manner analogous to the start date of follow-up. To evaluate total vaccine effectiveness, we compared the occurrence of first episodes of severely dehydrating cholera in recipients of a two-dose regimen of OCV in the combined intervention groups and age-eligible individuals (≥1 year) present at zero time (0·0–4·9 years and ≥5·0 years) and by year of follow-up. Heterogeneity

![Trial profile](Figure 1: Trial profile)

OCV=oral cholera vaccine. WASH=water-sanitation-hygiene. *The dose of dose 2 for the two-dose recipients or the median date of dose 2 of the cycle of vaccination for no-dose or one-dose recipients.*
of vaccine protection in these subgroups was assessed by analysing two-way interaction terms between the assigned group and subgroup variables in the models. The sample size for this cluster-randomised trial was calculated with the assumption of 80% power to detect vaccine total protection of 65%, a two-tailed p value smaller than 0·05, and an intra-cluster correlation coefficient (ICC) of 0·0004. The threshold of significance for individual estimates of protective effectiveness was p less than 0·05 with corresponding 95% CI (two-sided). All statistical analyses were done using SAS version 9.4. The study is registered at ClinicalTrials.gov number, NCT01339845.

Role of the funding source
The project was funded by the Bill & Melinda Gates Foundation, which provided inputs to the design and planning of the study. The funder had no role in data collection, data analysis, data interpretation, or writing of the report.

Results
In the 90 clusters, there were 268 896 individuals at zero time and 267 270 individuals at the start of follow-up, as described in the methods. The coverage of the OCV (two-dose recipients) in the two intervention groups was 66% (123 659 of 187 214 individuals). Of the 267 270 residents at the start of follow-up, 179 696 (67%) migrated out or died before completion of the 4 years of follow-up (figure 1). Figure 2 shows that these migration patterns resulted in a decline of vaccine coverage to 28% (35 353 of 125 149 participants) by the end of the 4-year follow-up.

For the analysis of overall vaccine effectiveness, we detected 441 first episodes of cholera with severe dehydration during the 4 years of follow-up, which were observed as 243 episodes in the vaccinated groups and as 198 episodes in the unvaccinated group. All cases were V cholerae O1 El Tor biotype; only six isolates were Inaba serotype. Figure 3 shows that event-free survival curves in the analysis of overall vaccine effectiveness continued to diverge with time of follow-up (p<0·0001, favouring the vaccine group). Cumulative 4-year overall protective effectiveness, after adjusting for covariates, was 36% (95% CI 19 to 49; p=0·0002; table 1). Point estimates of overall vaccine effectiveness were similar for people younger than 5 years (30%; 95% CI –8 to 55) and for people aged 5 years or older (36%; 95% CI 19 to 50; p=0·8128) at zero time in the intervention clusters. Analysis of overall effectiveness by year of follow-up revealed adjusted estimates that varied between 21% (95% CI –18 to 47) and 46% (95% CI 12 to 67), with no apparent decline with time (p=0·4050 for heterogeneity of the yearly estimates).

202 177 individuals were included in the analyses for assessing total protective effectiveness (appendix 2 p 1). Similar to the analysis of overall vaccine protection, in this analysis the two compared groups were well balanced with respect to baseline characteristics during each of the 4 years of follow-up (appendix 2 pp 11–18). For this analysis, there were 140 episodes of severely dehydrating cholera in the vaccinated groups and 192 episodes of severely dehydrating cholera in the control group. The event-free survival curves for patients assigned to the different groups of the study for evaluating total protective effectiveness are shown in the appendix 2 (p 2). The curves, which differed significantly (p<0·0001), continued to diverge over the entire period of follow-up. As shown in table 2, the adjusted value for cumulative total vaccine protection over the 4 years was 46% (95% CI 32 to 58; p<0·0001). Adjusted, cumulative total vaccine

See Online for appendix 2

Figure 2: Trend of two-dose oral cholera vaccine coverage (%) over 4 years of follow-up post-vaccination

*In the calculation of vaccine coverage, the numerator was all participants who received two-dose vaccines and who were under follow-up at each time point noted on the x-axis. Days in the x-axis begin with the time of the second dose for the intervention clusters.

Figure 3: Kaplan-Meier plot
The plot shows the estimates of the cumulative risk of not having cholera with severe dehydration among the entire population at zero time during 4 years of follow-up post-vaccination (overall vaccine efficacy analysis). The p value (p<0·0001) is two-tailed and calculated by the log-rank test. Note that, for demonstration purposes, the y axis of this plot goes from 0·990 to 1, not from 0 to 1. Days on the x-axis begin with the time of the second dose (ie, the start of follow-up), as described in the text.
The findings of our study show that a moderate level of overall and total OCV protection against severe cholera was sustained over the 4 years of follow-up for the study population in this trial. For reasons mentioned in the methods section, we combined the two vaccinated groups of the trial for this analysis, but in fact there was little difference in vaccine protection between the two groups. Point estimates for overall vaccine protection were similar for people younger than 5 years and for people aged 5 years or older. By contrast, point estimates for total vaccine protection were notably lower for young children than for older people, although the difference did not reach statistical significance. Both types of vaccine protection remained stable over the entire 4-year period of follow-up for the entire study population, although a marked decline in total vaccine protection in the 4th year was evident in children vaccinated before the age of 5 years.

Before discussing the implications of these findings, it is important to address several limitations of the study. First, this trial was not a blinded study. However, the similarity of our estimates of total vaccine protection to the estimates for protective effectiveness in a randomised, blinded, placebo-controlled trial of Shanchol in Kolkata, India, is reassuring. Second, 67% of the baseline population died or migrated out during the 4-year follow-up period. Fortunately, the losses to follow-up were unlikely to have biased our estimates because they

---

**Table 1: Incidence of severe cholera and cumulative overall protection by the killed whole-cell OCV during 4 years of follow-up**

| Year of follow-up | Participants aged ≥5 years | Participants aged <5 years |
|-------------------|-----------------------------|-----------------------------|
| 1st year          | 187,214                     | 243, 125,912,808            |
| 2nd year          | 104,799                     | 45, 32,589,219              |
| 3rd year          | 75,584                      | 77, 24,336,059              |
| 4th year          | 58,315                      | 46, 19,123,055              |

| Year of follow-up | Number of cholera episodes | Incidence per 100,000 person-days of follow-up (95% CI) | Crude estimate (95% CI) | Adjusted estimate (95% CI) | p value |
|-------------------|-----------------------------|----------------------------------------------------------|-------------------------|--------------------------|---------|
| 1st year          | 187,214                     | 59, 48,865,475                                            | 0.15 (0.12 to 0.19)     | 36 (0.27 to 0.45)        | 0.0050  |
| 2nd year          | 104,799                     | 50, 45, 32,589,219                                        | 0.14 (0.11 to 0.18)     | 32 (0.21 to 0.37)        | 0.0002  |
| 3rd year          | 75,584                      | 60, 77, 24,336,059                                        | 0.22 (0.25 to 0.24)     | 32 (0.22 to 0.35)        | 0.0050  |
| 4th year          | 58,315                      | 70, 58, 19,123,055                                        | 0.24 (0.18 to 0.32)     | 32 (0.22 to 0.35)        | 0.0050  |

---

The findings of our study show that a moderate level of overall and total OCV protection against severe cholera was sustained over the 4 years of follow-up for the study population in this trial. For reasons mentioned in the methods section, we combined the two vaccinated groups of the trial for this analysis, but in fact there was little difference in vaccine protection between the two groups. Point estimates for overall vaccine protection were similar for people younger than 5 years and for people aged 5 years or older. By contrast, point estimates for total vaccine protection were notably lower for young children than for older people, although the difference did not reach statistical significance. Both types of vaccine protection remained stable over the entire 4-year period of follow-up for the entire study population, although a marked decline in total vaccine protection in the 4th year was evident in children vaccinated before the age of 5 years.

---

**Articles**

www.thelancet.com/infection Vol 21 October 2021 1411
## Table 2: Incidence of severe cholera and cumulative total vaccine protection by the killed OCV during the 4 years of follow-up

| Intervention groups | Control group | Total effectiveness* |
|---------------------|---------------|----------------------|
| N Cholera episodes; person-days of follow-up | N Cholera episodes; person-days of follow-up | Crude estimate (95% CI) | Adjusted estimate (95% CI) | p value |
| **Overall** | **Overall** | **Overall** | **Overall** | **Overall** |
| **Participants** | | | | | |
| All participants | | | | | |
| Participants vaccinated aged <5 years | | | | | |
| Participants vaccinated aged ≥5 years | | | | | |

## Table 3: Incidence of severe cholera and cumulative total vaccine protection by the killed OCV by follow-up period and age at vaccination

| Intervention groups | Control group | Total effectiveness* |
|---------------------|---------------|----------------------|
| N Cholera episodes; person-days of follow-up | N Cholera episodes; person-days of follow-up | Crude estimate (95% CI) | Adjusted estimate (95% CI) | p value |
| **Overall** | **Overall** | **Overall** | **Overall** | **Overall** |
| **Participants** | | | | | |
| All participants | | | | | |
| Participants vaccinated aged <5 years | | | | | |
| Participants vaccinated aged ≥5 years | | | | | |

ICDDR,B—International Centre for Diarrhoeal Disease Research, Bangladesh. *Two-tailed 95% CIs and p values are given for the analyses. **Adjusted for age at zero time (years), individuals having reported diarrhoea within 6 months at the time of household registration, individuals living in a household using safe water source (household tap), individuals living in a household having only one room, individuals living in a household sharing water source with others, individuals living in a household using treated water (boiled, filtered, or chemical treatment), closer distance from the household to the nearest ICDDR,B hospital, percentage of individuals living in their own house in the cluster. ***Adjusted for individuals having reported diarrhoea within 48 h at the time of household registration, individuals living in a household using safe water source (household tap), individuals living in a household having only one room, individuals living in a household sharing water source with others, individuals living in a household using treated water (boiled, filtered, or chemical treatment), closer distance from the household to the nearest ICDDR,B hospital, and percentage of individuals living in their own house in the cluster. |
Articles

were quantitatively similar in magnitude in the intervention and control groups of the study, and the groups remained qualitatively similar in respect to demographic and clinical predictors of cholera throughout the follow-up period. However, the losses did diminish the statistical power of the study, particularly in the last years of the study. Third, we did not use a comparator agent for OCV in the control group. Although this absence would not be expected to bias our analyses of overall vaccine protection, analyses of total vaccine protection were based on the comparison of people who accepted the vaccine in the intervention group versus all people in the control group, including people who would have refused a control agent had it been offered. Because people who refuse a control agent might be at higher risk of cholera than people who do not refuse a control agent, inclusion of these people might have resulted in an overestimation of total vaccine protection.  

Fourth, and conversely, the design of our trial, which enrolled clusters of people in the middle of a densely populated slum population, permitted transmission of cholera from outside the clusters into the clusters. Such transmission has been shown in this trial to depress estimates of vaccine protection that include vaccine herd effects, such as total and overall vaccine protection.  

Fifth, because our analysis included only people present at baseline, overall OCV protection during each year of follow-up should be interpreted as an overall protection of those individuals in the vaccinated clusters who were present at baseline and who were followed up, rather than an overall protection of the entire population of the vaccinated clusters during follow-up. Finally, because our study was done in an endemic population that is regularly exposed to cholera, which might have acted to provide immunological boosting to people receiving the vaccine during post-vaccination follow-up, our results might not generalise to populations without endemic cholera. Our findings support the findings of an earlier trial of Shanchol in Kolkata, India, which showed that total vaccine protection was long-lived (at least 5 years in that trial) in people vaccinated aged 5 years or older, but shorter lived in children vaccinated aged 1–4 years.  

Indeed, point estimates, by year of follow-up, of protective efficacy in per-protocol analyses of the Kolkata trial and of total vaccine protection in the present analyses are very similar, except for the 3rd year of follow-up, in which protective efficacy in the Kolkata trial was 66% (95% CI 40% to 81%) whereas total protection was 25% (95% CI –13% to 51%) in the present analysis. Analyses of total vaccine protection in individuals younger than 5 years in the current trial and of direct protection of individuals younger than 5 years in the Kolkata trial both gave point estimates suggesting protection in the 3rd year of follow-up, although the point estimates were not significant in either trial. Even if the results do not provide absolute certainty about optimal intervals before vaccine boosting of children vaccinated before the age of 5 years, the data of these two trials suggest that, for populations with endemic cholera, boosting after 3 years of follow-up with Shanchol is rational for individuals younger than 5 years, whereas boosting at a longer time interval might be needed for individuals aged 5 years or older.  

In aggregate, these findings indicate that the protection conferred by a two-dose regimen of Shanchol is considerable, even in densely populated, south Asian urban slums in which the force of cholera infection is high. A global OCV stockpile funded by Gavi and coordinated by WHO contains Shanchol and an identical OCV marketed as Euvichol. As of the end of 2018, more than 55 million doses had been deployed to over 100 vaccine campaigns in 22 developing countries.  

Our findings are consistent with analyses of several of these deployments indicating that vaccine protection in diverse settings was remarkably consistent with those of the Kolkata trial.  

That said, the lower level and shorter duration of vaccine protection observed in young children in both the Kolkata and Dhaka trials indicates that research is needed to improve vaccine protection against cholera in this age group. Although analyses of the first 2 years of follow-up of the present trial did not show that the WASH intervention tested in this trial significantly improved OCV protection, and although a meta-analysis of trials of WASH interventions against cholera did not identify interventions with major protective effects,  it seems plausible that more effective WASH interventions implementable with the limited resources of low-income countries might protect against cholera and complement the protection conferred by OCVs.

Contributors

JDC, MA, and FQ conceptualised the analytic approaches, JDC and MA wrote the Article. DRK and FA did the statistical analysis and created the figures. KZ, AIK, MTI, JJ, FM, and JHK reviewed the Article. All authors wrote the Article. DRK and FA did the statistical analysis and created the figures. KZ, AIK, MTI, JJ, FM, and JHK reviewed the Article. All authors had full access to all the data in the study and had final responsibility for the decision to submit for publication. MA, FA, and DRK accessed and verified the data.

Declaration of interests

We declare no competing interests.

Data sharing

Data used for the analyses in this paper will be made available to all interested researchers following the published policies of the International Centre for Diarrhoeal Disease Research, Bangladesh and the International Vaccine Institute.

References

1 Ali M, Nelson AR, Lopez AI, Sack DA. Updated global burden of cholera in endemic countries. PLoS Negl Trop Dis 2013; 9: e0003832.

2 Bhattacharya SK, Sur D, Ali M, et al. 5-year efficacy of a bivalent killed whole-cell oral cholera vaccine in Kolkata, India: a cluster-randomised, double-blind, placebo-controlled trial. Lancet Infect Dis 2013; 13: 1050–56.

3 Franke MF, Terrier R, Jerome JG, Matias WR, Harris JB, Ivers LC. Long-term effectiveness of one and two doses of a killed, bivalent, whole-cell oral cholera vaccine in Haiti: an extended case-control study. Lancet Glob Health 2018; 6: e1028–35.

4 Thiem VD, Deen JL, von Seidlein L, et al. Long-term effectiveness against cholera of oral killed whole-cell vaccine produced in Vietnam. Vaccine 2006; 24: 4297–303.

5 Clemens JD, Sack DA, Harris JR, et al. Field trial of oral cholera vaccines in Bangladesh: results from three-year follow-up. Lancet 1996; 335: 70–73.
6 Qadri F, Ali M, Chowdhury F, et al. Feasibility and effectiveness of oral cholera vaccine in an urban endemic setting in Bangladesh: a cluster randomised open-label trial. Lancet 2015; 386: 1362–71.
7 Khan IA, Saha A, Chowdhury F, et al. Coverage and cost of a large oral cholera vaccination program in a high-risk cholera endemic urban population in Dhaka, Bangladesh. Vaccine 2013; 31: 6058–64.
8 Clemens J, Shin S, Ali M. New approaches to the assessment of vaccine herd protection in clinical trials. Lancet Infect Dis 2011; 11: 482–87.
9 Najnin N, Leder K, Qadri F, et al. Impact of adding hand-washing and water disinfection promotion to oral cholera vaccination on diarrhoea-associated hospitalization in Dhaka, Bangladesh: evidence from a cluster randomized control trial. Int J Epidemiol 2017; 46: 2056–66.
10 WHO. The treatment of diarrhoea: a manual for physicians and other senior health workers (4th revision). https://apps.who.int/iris/bitstream/handle/10665/43209/9241593180.pdf?sequence=1&isAllowed=y (accessed June 1, 2020).
11 Ansaruzzaman M, Bhuiyan NA, Nair BG, et al. Cholera in Mozambique, variant of Vibrio cholerae. Emerg Infect Dis 2004; 10: 2057–59.
12 Halloran ME, Struchiner C, Longini IM Jr. Study designs for evaluating different efficacy and effectiveness aspects of vaccines. Am J Epidemiol 1997; 146: 789–803.
13 Lin DY, Wei L-J. Checking the Cox model with cumulative sums of martingale-based residuals. Biometrika 1993; 80: 557–72.
14 Lin DY, Wei L-J. The robust inference for the Cox proportional hazards model. J Am Stat Assoc 1989; 84: 1074–78.
15 Reid N, Crampes H. Influence functions for proportional hazards regression. Biometrika 1985; 72: 1–9.
16 Lee EW, Wei LJ, Amato DA, Leurgans S. Cox-type regression analysis for large numbers of small groups of correlated failure time observations. In: Klein JP, Goel PK. Survival analysis: state of the art. Berlin: Springer, 1992: 237–47.
17 Clemens JD, van Looon FF, Rao M, et al. Nonparticipation as a determinant of adverse health outcomes in a field trial of oral cholera vaccines. Am J Epidemiol 1992; 135: 865–74.
18 Ali M, Qadri F, Kim DR, et al. Unmasking herd protection by an oral cholera vaccine in a cluster-randomized trial. Int J Epidemiol 2019; 48: 1252–61.
19 Pezzoli L. Global oral cholera vaccine use, 2013–2018. Vaccine 2020; 38 (suppl 1): A132–40.
20 Martin S, Lopez AI, Bellos A, et al. Post-licensure deployment of oral cholera vaccines: a systematic review. Bull World Health Organ 2014; 92: 881–93.
21 Taylor DL, Kahawita TM, Cairncross S, Ensink JH. The impact of water, sanitation and hygiene interventions to control cholera: a systematic review. PLoS One 2013; 8(10): e70156.076.